Employees: 1-10
Investment Stage: Seed; Series A; Series B
Portfolio 36
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| 22.09.2024 | Sab Biothe... | sab.bio | - | United Sta... |
| 22.09.2024 | Jaguar Gen... | jaguargenetherapy.com | - | United Sta... |
| 22.09.2024 | Cour Pharm... | courpharma.com | $135M | United Sta... |
| 22.09.2024 | Orizuru Th... | orizuru-therapeutics.com | - | - |
| 22.09.2024 | Eledon Pha... | eledon.com | - | United Sta... |
| 10.03.2024 | Sana Biote... | sana.com | $2.79B | United Sta... |
| 10.03.2024 | vTv Therap... | vtvtherapeutics.com | - | United Sta... |
| 10.05.2023 | DiogenX | diogenx.com | $35.2M | France, Pr... |
| 02.08.2022 | Egle Thera... | egle-tx.com | $10.54M | France, Il... |
Show more
Persons 7
| Date | First Name | Last Name | Title | Location | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| - | Clay | Rowland | Associate | linkedin.c... | - | c******d@t... | - |
| - | Nandan | Padukone | - | linkedin.c... | - | N*******e@... | - |
| - | Sean | O'Connor | Principal | - | - | - | |
| - | Katie | Ellias | Managing D... | linkedin.c... | - | k*****s@t1... | - |
| - | Yury | Kukushkin | - | linkedin.c... | - | y********n... | - |
| - | William | Orent | Associate | linkedin.c... | - | w****t@t1d... | - |
Mentions in press and media 27
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| 11.09.2025 | Kriya Raises $320M in Series D Financing | Kriya Therapeutics, a Research Triangle Park, NC-based clinical-stage biopharmaceutical company developing gene therapies for chronic diseases of high unmet need, raised $320M in Series D financing. The round was co-led by Patient Square Ca... |
| 03.05.2025 | Zucara Therapeutics Secures $25 Million to Combat Diabetes Complications | Zucara Therapeutics is on a mission. The Toronto-based company is tackling a significant challenge in diabetes management: hypoglycemia. Recently, Zucara completed its Series B financing, raising a total of $25 million. This funding is a li... |
| 02.05.2025 | Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences Platform | Zucara Therapeutics – a diabetes life sciences company developing ZT-01, which is the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes – announced that it has completed the second and f... |
| 01.05.2025 | Zucara Therapeutics Raises $5M in Second and Final Closing of US$25M Series B Financing | Zucara Therapeutics Inc., a Toronto, Canada-based diabetes life sciences company, raised $US5m in the second and final closing of its US$25m Series B financing. The T1D Fund: A Breakthrough T1D Venture, and other new investors invested a co... |
| 19.03.2025 | Egle Therapeutics Secures €9.3 Million to Advance Immuno-Oncology Research | Egle Therapeutics is on the rise. The Paris-based biotechnology company has just secured €9.3 million in state funding. This investment comes from the French government’s France 2030 initiative, specifically under the “Innovations in Biothe... |
| 18.03.2025 | Egle Therapeutics: €9.3 Million In State Funding Raised To Develop Therapies Targeting Regulatory T Cells | Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, announced that it secured €9.3 million in state funding under the Innovations i... |
| 09.01.2025 | Aspect Biosystems Raises US$115M in Series B Financing | Aspect Biosystems, a Vancouver, BC, Canada-based biotechnology company developing bioprinted tissue therapeutics for the regenerative medicine, raised US$115M in Series B funding. The round was led by Dimension, with participation from exis... |
| 25.06.2024 | Breakthrough T1D-Funded Research Featured at American Diabetes Association 84th Scientific Sessions | NEW YORK, June 25, 2024 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the America... |
| 28.02.2024 | vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund | - |
Show more